Sema4 builds data-driven, patient-centered health intelligence to generate dynamic models of human health and define individualized health trajectories. Its Centrellis platform underpins the company’s analytics and predictive modeling capabilities. Sema4 began with an emphasis on reproductive health and has expanded into precision oncology with the Sema4 Signal family of products and services. The company has also deployed clinical, scientific and digital capabilities to support COVID-19 testing programs. Sema4 was spun out of the Mount Sinai Health System in June 2017 and is led by founder and CEO Eric Schadt; several high-profile industry and regulatory leaders have recently joined its board. The company recently closed a large financing to support continued rapid growth and investment in precision medicine solutions.

Total raised

$121M

Funding rounds

1

Latest round

Series C

Latest activity

Jul 2020